tbuckley/cabot-search huggingface dataset:
CD55, a potential immunotherapeutic target for<i>MYCN</i>-amplified neuroblastoma
Authors: Hiroyuki Yoda, William A Weiss
Journal: Neuro-Oncology (2022)

Neuroblastoma, a pediatric tumor arising from human neural crest cells (hNCCs), is the most common extracranial solid tumor of childhood.1 Patients are stratified into risk groups, and patients with high-risk disease show poor survival. Immunotherapy using antibodies to GD2, a disialoganglioside expressed on the surface of neuroblastoma cells, has improved survival dramatically in children with high-risk neuroblastoma, however, nearly half of patients relapse, and little is known about mechanisms of resistance.2,3 Clinical trials using chimeric antigen receptor (CAR) T cells directed against GD2 have shown mixed results.3 The ideal marker for immunotherapy is both tumor-specific and required for malignant progression. As an example, CAR T cells that recognize the transmembrane protein CD19, an essential protein for B-lymphocyte survival, have shown remarkable activity in children with acute leukemia.4,5 Challenges for immunotherapy in neuroblastoma include the barren immune landscape and a paucity of tumor-specific surface proteins that are also required for ongoing tumorigenesis. In this issue of Neuro-Oncology,6 Weng et al present preliminary findings suggesting CD55 as a protein that meets this latter requirement.
BOOK REVIEWS
Authors: T. HORN
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Get access Cancer of the Skin R.J. Friedman , D.S. Rigel , A.W. Kopf , M.N. Harris , D. Baker eds. Philadelphia : Saunders , 1990 , 640 pp. $155. THOMAS HORN THOMAS HORN Division of Dermatopathology and Oral Pathology, The Johns Hopkins Medical Institutions 600 N. Wolfe St.Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 16, 21 August 1991, Page 1176, https://doi.org/10.1093/jnci/83.16.1176 Published: 21 August 1991
Erratum
Journal: BMJ (1904)

might find that his case of chronic gleetwould cease if the treatment by santal oil be discontioued very gradually and not suddenly.Failing this, it is necessary to know whether the anterior or posterior urethra or both are infected, so that suitable treatment be adopted.I would suggest that the "two-glass test" be applied to arrive at these conclusions, after whicha thorough urethroscopic examination, with topical application of silver nitrate, gr.v. to x. to 33, to the lesion found, or dilatation of the urethra with a Kollman's diuator, and subsequent irrigation of the canal be carried out.By these means most, if not all, chronic gleets can be cured.LNTEUR.NYOTNI.Uk.VERON AL.D. J
The CARD14 Variant Rs11652075 Interacts with Vitamin D3 to Confer Barrier Dysfunction and Atopic Dermatitis Risk
Authors: Stanley DeVore, Matthew Schuetz, Melissa MacDonald, Arjun Kothari, Brittany Grashel, Elisabet Johansson, Hua He, Jocelyn Biagini, John Kroner, Lisa Martin, Gurjit Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2022)
Vasopressin and Methylprednisolone vs Placebo and Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest
Authors: Richard Jiménez-Cuja, Victor Salazar-Orihuela, Luis Llanco-Albornoz
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P075: Control of Cardiovascular Risk Factors Among Older Adults With Incident Diabetes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Authors: Gargya Malla, Andrea Cherrington, Sha Zhu, Doyle M Cummings, Olivio Clay, Todd M Brown, Loretta T Lee, Ruth Kimokoti, Mary Cushman, Monika M Safford, April P Carson
Journal: Circulation (2019)

Background: Control of risk factors is important for the primary prevention of cardiovascular disease among adults with diabetes. The objective of this study was to determine whether management of clinical (hemoglobin A1c &lt;8%; BP &lt;130/80 mm Hg; and statin use) and lifestyle factors (not currently smoking; physical activity on 4+ days/week; and moderate or no alcohol use) varied by race and sex among older adults with incident diabetes. Methods: This study included 1,420 Black and White adults from the REGARDS Study with incident diabetes at the follow-up exam (2014-16). Incident diabetes was defined as fasting glucose&gt;=126 mg/dL, random glucose&gt;=200 mg/dL, or use of diabetes medications among those without diabetes at baseline (2003-07). Modified Poisson regression was used to obtain prevalence ratios (PR) for the control of risk factors for Black versus White adults and assess race-sex interactions. Results: The mean age was 71.5 years, 53.6% were female, 46.1% were Black and 85.7% reported they were aware of their diabetes. BP control was lower for Black males than White males (p=0.0036), whereas statin use was lower for Black females than White females (p=0.0241). For lifestyle factors, not smoking was lower for Black males than White males (p=0.0187), whereas moderate or no alcohol use was higher for Black females than White females (p&lt;0.0001). (Figure) Race-sex interactions were not statistically significant. In age and sex-adjusted models, Black adults were less likely to have BP controlled (PR=0.89; 95% CI=0.81, 0.99) or use statins (PR=0.88; 95% CI=0.80, 0.97) and more likely to report moderate or no alcohol use (PR=1.05; 95% CI=1.03, 1.07) than White adults. Control of other factors was similar. Conclusion: Although control of individual risk factors was generally high among older adults with incident diabetes, racial differences in BP control and statin use were apparent. Assessment and management of cardiovascular risk factors in this high-risk population remains important for prevention.
MULTIVESSEL CORONARY REVASCULARIZATION IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS 5-YEAR FOLLOW-UP OF THE ARTS-II TRIAL (ARTERIAL REVASCULARIZATION THERAPIES STUDY-PART II)
Authors: Yoshinobu Onuma, Joanna Wykrzykowska, Pascal Vranckx, Patrick W. Serruys, None the ARTS-II Investigators
Journal: Journal of the American College of Cardiology (2010)
Feasibility and safety of using a novel traction wire for endoscopic submucosal dissection of challenging gastrointestinal neoplasia
Authors: Shahila Perveen Aslam, Mohamed Abdelrahim, Sharmila Subramaniam, Pradeep Bhandari
Journal: Endoscopy (2022)

Endoscopic submucosal dissection (ESD) is an en bloc resection technique for gastrointestinal neoplasia but is associated with high risk of complications [1]. The ProdiGI traction wire (Medtronic, Minneapolis, Minnesota, USA) is a novel device for improving the safety of ESD.
Books Received
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Remote patient monitoring in COVID-19: a critical appraisal
Authors: Henri Gruwez, Emma Bakelants, Pauline Dreesen, Jolien Broekmans, Maarten Criel, Michiel Thomeer, Pieter Vandervoort, David Ruttens
Journal: European Respiratory Journal (2022)

With great interest, we read the article by Grutters et al . [1], in which they share their results of the largest patient cohort of coronavirus disease 2019 (COVID-19) home monitoring to date. Based on these results, remote patient monitoring (RPM) was praised and was claimed as a tool to reduce the hospital stay of COVID-19 patients by 5 days. Is there any evidence for #telemonitoring in #COVID19? Read more: <https://bit.ly/3p1YXBi>
Early Detection of Tumor Response to Chemotherapy by 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model <i>In vivo</i>
Authors: Julius Leyton, John R. Latigo, Meg Perumal, Harmandeep Dhaliwal, Qimin He, Eric O. Aboagye
Journal: Cancer Research (2005)

We have assessed the potential of [18F]fluorothymidine positron emission tomography ([18F]FLT-PET) to measure early cytostasis and cytotoxicity induced by cisplatin treatment of radiation-induced fibrosarcoma 1 (RIF-1) tumor-bearing mice. Cisplatin-mediated arrest of tumor cell growth and induction of tumor shrinkage at 24 and 48 hours, respectively, were detectable by [18F]FLT-PET. At 24 and 48 hours, the normalized uptake at 60 minutes (tumor/liver radioactivity ratio at 60 minutes after radiotracer injection; NUV60) for [18F]FLT was 0.76 +/- 0.08 (P = 0.03) and 0.51 +/- 0.08 (P = 0.03), respectively, compared with controls (1.02 +/- 0.12). The decrease in [18F]FLT uptake at 24 hours was associated with a decrease in cell proliferation assessed immunohistochemically (a decrease in proliferating cell nuclear antigen labeling index, LI(PCNA), from 14.0 +/- 2.0% to 6.2 +/- 1.0%; P = 0.001), despite the lack of a change in tumor size. There were G1-S and G2-M phase arrests after cisplatin treatment, as determined by cell cycle analysis. For the quantitative measurement of tumor cell proliferation, [18F]FLT-PET was found to be superior to [18F]fluorodeoxyglucose-PET (NUV60 versus LIPCNA: r = 0.89, P = 0.001 and r = 0.55, P = 0.06, respectively). At the biochemical level, we found that the changes in [18F]FLT and [18F]fluorodeoxyglucose uptake were due to changes in levels of thymidine kinase 1 protein, hexokinase, and ATP. This work supports the further development of [18F]FLT-PET as a generic pharmacodynamic readout for early quantitative imaging of drug-induced changes in cell proliferation in vivo.
TCT-175 A First-in-Man Study of the Bioheart Sirolimus-Eluting Bioresorbable Scaffold in Patients With Coronary Artery Disease: 2-Year Clinical and Imaging Outcomes
Authors: Md Misbahul Ferdous, Yongjian Wu, Changdong Guan, Zhongwei Sun, Bo Xu
Journal: Journal of the American College of Cardiology (2019)
<i>Text-Book on Nervous Diseases</i>. By G. Aschaffenburg; H. Cursciimann; R. Finkelnburg; R. Gaupp; G. Hirsch; Fr. Jamin; J. Ibrahim; Fedor Krause; M. Lewandowsky; H. Liepmann; L. R. Müller; H. Schlesinger; S. Schoenborn; H. Starck and H. Steinert. Authorized English Edition, Edited by Charles W. Burr, M. D., Pofessor of Mental Diseases in the University of Pennsylvania, etc. With 156 Text Illustrations—In two volumes. (<i>Philadelphia: P. Blakiston’s Son and Company, 1915</i>.)
Journal: American Journal of Psychiatry (1916)
Special Article
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infectious Disease
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combo Approaches for HPV16+ Cancers
Journal: Cancer Discovery (2021)

Beyond anti-PD-1 therapy as a mainstay, additional strategies are being developed for HPV-associated cancers. Emerging data from two ongoing trials have shown some early efficacy with vaccines directed at HPV16-specific E6 and E7 viral oncoproteins, as well as with other therapies targeting different facets of antitumor immunity.
The Humoral Immune Response To SARS-CoV-2 Infection And/or Immunization in Immunocompromised Versus Immunocompetent Individuals
Authors: Peter Illes, Krisztian Csomos, Boglarka Ujhazi, Joseph Dasso, Bence Nagy, Eugenia Alas, Sumai Gordon, Priyanka Timothy, Mary Ann Miranda, Shannon Sullivan, Panida Sriaroon, Ann Marie Szymanski, Jolan Walter
Journal: Journal of Allergy and Clinical Immunology (2022)
Strengthening the Medicaid Reentry Act — Supporting the Health of People Who Are Incarcerated
Authors: Utsha G. Khatri, Tyler N.A. Winkelman
Journal: New England Journal of Medicine (2022)

Under the Reentry Act, Medicaid would be able to pay for health care for eligible people who are incarcerated starting up to 30 days before their release from jail or prison. Changes to this bill could bring care in these facilities in line with community standards.
Diffusing Capacity of the Lungs for Carbon Monoxide Test
Authors: Neil MacIntyre, Aparna Balasubramanian, David Kaminsky
Journal: JAMA (2022)

A 62-year-old man presented with a 4- to 6-month history of increasing exertional dyspnea. His measured hemoglobin was 15.3 g/dL and diffusing capacity of the lungs for carbon monoxide was 9.80 mL/min/mm Hg. How would you interpret these test results?
Current Comment
Journal: JAMA (1910)

<h3>TEACH THE TEACHERS</h3> The September number of the<i>Bulletin of the North Carolina Board of Health</i>is a teachers' edition, specially prepared for the instruction of the public school teachers of the state. It contains articles on the importance of the recognition of physically defective children, the movement for oral hygiene in the public schools and its importance, the medical inspection of public school children, the value of science teaching in the grades and high schools, and the relation of childhood and youth to public health. Illustrations show the dangers of the common drinking-cup. Such bulletins issued under the authority of the state board of health and distributed to school teachers, parents, and pupils of the high schools are a most valuable means of public instruction on sanitary and hygienic questions. <h3>CONTAMINATED WATER-SUPPLIES AND SENSITIVE OFFICIALS</h3> In one of the most important reports of recent years on typhoid fever in
Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study
Authors: Céline Ben Hassen, Aurore Fayosse, Benjamin Landré, Martina Raggi, Mikaela Bloomberg, Séverine Sabia, Archana Singh-Manoux
Journal: BMJ (2022)

Abstract Objective To examine the association of midlife and late life multimorbidity, including severity of multimorbidity, with incident dementia. Design Prospective cohort study. Setting Civil service departments in London (Whitehall II study, study inception in 1985-88). Participants 10 095 participants, aged 35 to 55 at baseline. Main outcome measure Incident dementia at follow-up between 1985 and 2019. Cause specific Cox proportional hazards regression was used to examine the association of multimorbidity overall and at age 55, 60, 65, and 70 with subsequent dementia, taking into account the competing risk of death. Results The prevalence of multimorbidity (≥2 chronic diseases) was 6.6% (655/9937) at age 55 and 31.7% (2464/7783) at age 70; 639 cases of incident dementia occurred over a median follow-up of 31.7 years. After adjustment for sociodemographic factors and health behaviours, multimorbidity at age 55 was associated with subsequent risk of dementia (difference in incidence rate per 1000 person years 1.56, 95% confidence interval 0.62 to 2.77; hazard ratio 2.44, 95% confidence interval 1.82 to 3.26). The association weakened progressively with older age at onset of multimorbidity. At age 65, onset of multimorbidity before age 55 was associated with 3.86 (1.80 to 6.52) per 1000 person years higher incidence of dementia (hazard ratio 2.46, 1.80 to 2.26) and onset between 60 and 65 was associated with 1.85 (0.64 to 3.39) per 1000 person years higher incidence (1.51, 1.16 to 1.97). Severity of multimorbidity (≥3 chronic diseases) at age 55 was associated with a 5.22 (1.14 to 11.95) per 1000 person years higher incidence of dementia (hazard ratio 4.96, 2.54 to 9.67); the same analyses at age 70 showed 4.49 (2.33 to 7.19) per 1000 person years higher incidence (1.65, 1.25 to 2.18). Conclusion Multimorbidity, particularly when onset is in midlife rather than late life, has a robust association with subsequent dementia. The increasingly younger age at onset of multimorbidity makes prevention of multimorbidity in people with a first chronic disease important.
Abstract 311: One-year Outcomes of DPP-4 Inhibitor Treatment in Diabetic Patients After Contemporary Percutaneous Coronary Intervention - Ps Matching from Data of Multicenter Registry -
Authors: Takehiro Hata, Nobuhisa Hagiwara, Kentaro Jujo
Journal: Circulation (2020)

Introduction: Clinical prognosis in diabetic patients comorbid with coronary artery disease (CAD) remained poor, even in the current drug-eluting stent (DES) era. However, there has been a limited evidence about the prognosis in diabetic patients with CAD who were treated with dipeptidyl peptidase-4 inhibitors (DPP4i). Methods: This study is a subanalysis from the TWINCRE registry that is a multicentral prospective cohort including patients who underwent percutaneous coronary intervention (PCI) at 12 hospitals in Japan between 2017 and 2019. Among 1,905 registered patients who were followed up, we ultimately evaluated 615 diabetic patients. They were divided into two groups depending on the prescription of DPP4i at the hospital discharge after the index PCI; DPP4i group (n=287) and Non-DPP4i group (n=328). For the two groups, we performed propensity-score (PS) matching using variables as follows: age, sex, acute coronary syndrome, left ventricular ejection fraction, serum creatinine, insulin use, prescriptions of statin, beta blocker, aspirin, and ACE inhibitor/ARB. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) including death, acute coronary syndrome, stent thrombosis, hospitalization due to heart failure and ischemic stroke. Results: Overall MACCE was observed in 70 patients (11.4%) during 364 days of median observation period. In unmatched patients, Kaplan-Meier analysis showed that patients in the DPP4i group showed a significantly lower MACCE rate than those in the Non-DPP4i group (Log-rank test, p=0.009, Figure A). In 284 PS-matched patients, patients in the DPP4i group still had lower MACCE rate than those in the non-DPP4i group (hazard ratio 0.39, 95% confidence interval 0.16-0.96, p=0.034, Figure B). Conclusion: Propensity-matching analysis showed that hyperglycemia control by DPP4i was associated with better 1-year clinical outcomes in diabetic patients after PCI in the contemporary DES era.
Industrial Exhibits
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal